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Carbamazepine (CBZ) causes life- threating T- cell- mediated hypersensitivity reactions, including serious cutaneous 
adverse reactions (SCARs) and drug- induced liver injury (CBZ- DILI). In order to evaluate shared or phenotype- specific 
genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta- analysis of two genomewide 
association studies (GWAS) on a total of 43 well- phenotyped Northern and Southern European CBZ- SCAR cases 
and 10,701 population controls and a GWAS on 12 CBZ- DILI cases and 8,438 ethnically matched population 
controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ- SCAR (odds ratio 
(OR) = 8.0; 95% CI 4.10–15.80; P = 1.2 × 10−9) and CBZ- DILI (OR = 7.3; 95% CI 2.47–23.67; P = 0.0004) in 
European populations. The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity 
syndrome (OR = 12.9; P = 2.1 × 10−9) rather than by Stevens- Johnson syndrome/toxic epidermal necrolysis cases, 
which showed an association with HLA-B*57:01. We also identified a novel risk locus mapping to ALK only for CBZ- 
SCAR cases, which needs replication in additional cohorts and functional evaluation.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Carbamazepine (CBZ) is associated with serious, and some-
times fatal, cutaneous and liver adverse reactions. Genomewide 
profiling has shown that these predisposing factors largely re-
side in the HLA region (HLA-B*15:02 and HLA-A*31:01) 
consistent with the immune pathogenesis.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What are the genetic predisposing factors in Northern and 
Southern European populations for CBZ- induced hypersensi-
tivity reactions affecting both the skin and liver?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 Genetic profiling confirmed that HLA-A*31:01 predisposes 
to serious cutaneous adverse reaction (SCAR) in both Northern 
and Southern European populations. HLA-A*31:01 also seems 
to predispose to CBZ- induced liver injury. In addition, an un-
common variant in the ALK gene was associated with an in-
creased risk of CBZ- SCAR.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
 Our study adds to the overwhelming evidence of the role of 
HLA-A*31:01 in predisposing to a variety of CBZ hypersensi-
tivity phenotypes and highlights the need to implement its pre- 
prescription and preemptive use in clinical settings.
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Carbamazepine (CBZ) is prescribed for epilepsy, trigeminal neu-
ralgia, and bipolar disorder.1 In 3–10% of patients, CBZ causes 
a variety of hypersensitivity reactions,2 ranging from mild mac-
ulopapular exanthemas to hypersensitivity syndrome, drug reac-
tion with eosinophilia and systemic symptoms (DRESS), acute 
generalized exanthematous pustulosis (AGEP), Stevens-Johnson 
syndrome (SJS), and toxic epidermal necrolysis (TEN); the latter 
four phenotypes are referred to as serious cutaneous adverse reac-
tions (SCARs). CBZ can also lead to liver injury, which can occur 
either as part of DRESS or in isolation (the latter is referred to 
as CBZ- drug- induced liver injury (DILI) in this paper).3,4 These 
unpredictable clinical phenotypes are T- cell- mediated, in which 
CBZ and/or its metabolites bind specific HLA molecules trigger-
ing a T- cell response.5
CBZ- induced SJS/TEN is strongly associated with HLA-
B*15:02 in Han Chinese, Thais, and Malays,6 whereas HLA-
A*24:02 has also recently been identified as a risk factor in Han 
Chinese.7 HLA-A*31:01 is associated with a variety of CBZ- 
SCAR phenotypes and maculopapular exanthema in Japanese,8 
Korean,9 and European- descent populations.10 Several other HLA 
loci have been suggested as susceptibility loci, including HLA-
A*02:06,8 HLA-B*15:11,11 and HLA-B*51:01,12–14 but the find-
ings have not always been replicated.15 Currently, we have limited 
knowledge of susceptibility loci for CBZ- DILI.
The purpose of our study was to perform a meta- analysis be-
tween our previously published CBZ hypersensitivity cohort10 
and a newly recruited cohort in order to increase study power and 
further investigate (i) novel risk loci within and outside the HLA 
region, and (ii) the role of HLA-A*31:01 stratifying by European 
subpopulations and clinical phenotypes, including SCAR and 
DILI.
RESULTS
Case collection and population structure
Our meta- analysis included a total of 43 CBZ- SCAR cases and 
10,701 population controls from two genomewide association 
studies (GWAS) studies: British GWAS (14 cases and 2,263 con-
trols) and broadly European GWAS (29 SCAR cases and 8,438 
controls). The British GWAS included Northern European 
patients from the United Kingdom, which we have reported 
previously.10 The broadly European GWAS included a newly re-
cruited set of CBZ- SCAR cases with different clinical phenotypes 
(Table 1) and European ancestries (Figure S1). The inferred pop-
ulation structure of the combined cohorts is shown in Figure 1. 
A summary of the clinical characteristics of the SCAR cases is 
provided in Table 1. We analyzed 25 patients with DRESS, 16 
patients with SJS/TEN, and 2 patients with AGEP. The average 
age of patients at the time of adverse reaction was 34 years in both 
study phases. Nearly two-thirds (63%) of cases were women.
Separately, we recruited 12 patients with CBZ- DILI of European 
descent (Figure 1). The type of liver injury in these patients was 
50% hepatocellular and 50% cholestatic/mixed. None of them had 
cutaneous involvement or eosinophilia. Their clinical characteris-
tics are also provided in Table 1. CBZ- DILI cases were compared 
with the 8,438 controls from the broadly European cohort.
Meta- analysis of CBZ- SCAR
After quality control of the imputed data, we retained 5,271,349 
single nucleotide polymorphisms (SNPs) for association analyses. 
Our meta- analysis identified two loci attaining genomewide sig-
nificance (P < 5 × 10−8):
• The strongest association signal mapped to the major histo-
compatibility complex (MHC; lead SNP rs192543598; odds 
ratio (OR)  =  18.1; 95% CI 8.03–40.90; P  =  1.7  ×  10−12; 
Pperm < 5 × 10
−8; Table 2, Table S1, Figure 2, and Figure S2), 
consistent with our previous result.10
• A novel association signal mapping to the ALK gene was ob-
served outside the MHC (lead SNP rs187926838; OR = 12.1; 
95% CI 4.94–29.80; P  =  4.9  ×  10−8; Pperm  =  1  ×  10
−7; 
Table 2 and Figure S3). The intronic lead SNP showed a con-
sistent directional effect in both GWAS and was carried by 6% 
of the cases. The imputation for rs187926838 had high accuracy 
across the imputation batches (info score > 0.9). The frequency 
of rs187926838 in our control population was equal to the allele 
frequency reported in Europeans in gnomad (http://gnomad.
broad insti tute.org/) and similar across platforms (Table 1 and 
Table S1), confirming the accuracy of the predicted genotypes. 
The rs187926838 showed a similar frequency in the SANAD 
study cohort,2 which has been exposed to a number of anti-epi-
leptic drugs, including CBZ (allele frequency = 0.005).
Dissection of the MHC CBZ- SCAR association signal
The lead SNP representing the MHC CBZ- SCAR associa-
tion signal, rs192543598, was in strong linkage disequilibrium 
(LD) with HLA-A*31:01 (r2 = 0.75). The HLA class I allele also 
reached genomewide significance in the meta- analysis (OR = 8.0; 
95% CI 4.10–15.80; P = 2.2 × 10−9; Pperm < 5 × 10
−8; Table 3 and 
Table S2). The phase II GWAS showed an MHC- wide HLA-
A*31:01 association, replicating the previously reported signal.
The HLA-A*31:01 association was less significant in the 
broadly European cases than in the British cases, probably because 
of greater heterogeneity in their geographic origin (Figure 1). A 
lower allele frequency was observed in the Spanish cases (6%) com-
pared with other ethnic groups (15% in Northern European and 
13% Italian cases) despite an equivalent frequency in the three con-
trol groups. However, the effect of HLA-A*31:01 was conserved 
in all European populations (ORItalian = 8.7; ORSpanish = 3.66; and 
ORNorth Europeans  =  5.51). There were no differences in allele fre-
quencies of the GWAS variants in control groups despite the dif-
ferent genotyping arrays used.
Reciprocal conditional analyses demonstrated that rs192543598 
and HLA-A*31:01 represent the same underlying association sig-
nal (Table S2). After conditioning on the lead SNP, rs192543598, 
we observed some evidence for residual association (at locus- 
wide significance, P  <  10−5) with CBZ- SCAR, mapping to 
MUC22 (lead SNP rs116071718, OR = 4.0; 95% CI 2.25–7.05; 
P = 1.5 × 10−6; Table S2 and Figure S4). After conditioning on 
both rs192543598 and rs116071718, the association signal with 
CBZ- SCAR in the MHC was fully accounted for (Figure S4).
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Marginal associations were also identified with HLA-B*51:01 
and HLA-C*15:02 (Table 3). These HLA alleles along with HLA-
A*31:01 constitute an uncommon haplotype present in European 
descent individuals (http://www.allel efreq uenci es.net). Joint 
carriage of the three alleles had a stronger signal compared with 
HLA-A*31:01 alone (OR  =  22.1, P  =  2.4  ×  10−6 vs. OR  =  5.7, 
P = 6.6 × 10−6; Table S3).
Assessment of polymorphic amino acid residues in HLA 
molecules
Predisposition to CBZ- SCAR may be related to the same essen-
tial amino acid (AA) residues in different HLA alleles. Therefore, 
we performed an aggregated investigation by analyzing the poly-
morphic AA residues at these proteins. The strongest association 
was observed for isoleucine73 on the HLA-A locus (OR = 5.5; 95% 
Table 1 Clinical information of the CBZ- SCAR and CBZ- DILI cases included in the studya
Phenotype Category Phase I cases Phase II cases
SCAR Total number of cases 14 29
Age at the onset in years (mean) 34 34
Gender (% female) 43% 66%
Allergy (% yes) 36% 24%
Clinical subphenotypes
AGEP 1 1
Hypersensitivity syndrome (DRESS) 13 12
SJS 0 5
SJS/TEN 0 10
TEN 0 1
Systemic symptoms
Eosinophilia 6 6
Liver involvement 0 10
Fever 13 22
Pneumonitis 2 0
Multi- organ failure, death 1 0
Additional evidences for the diagnosis
Skin biopsy 1 8
Skin patch testing performed 1 5
Multiple drug- induced skin reactions 3 1
DILI Total number of cases 0 12
Age at the onset in years (mean) – 37.6
Gender (% female) – 67%
Pattern of liver injury
Cholestatic – 3
Mixed – 2
Hepatocellular – 5
Unknown – 2
Systemic symptoms
Eosinophilia – 0
Cutaneous rashes – 0
RUCAM scoreb
3–5 (possible) – 2
6–8 (probable) – 6
> 8 (highly probable) – 2
AGEP, acute generalized exanthematous pustulosis; CBZ, carbamazepine; DILI, drug- induced liver injury; DRESS, drug reaction with eosinophilia and systemic 
symptoms; RUCAM, Roussel Uclaf Causality Assessment Method; SCAR, serious cutaneous adverse reaction; SJS, Stevens- Johnson syndrome; TEN, toxic 
epidermal necrolysis.
aEach patient can have more than one clinical characteristic; therefore, the numbers do not add up to the number of patients in phases I and II of the study. 
bRUCAM scores were not possible for two patients recruited previously in the study of McCormack et al.10 because of the lack availability of all clinical 
information. Causality had been undertaken using temporal relationship to drug intake and exclusion of other causes.
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 106 NUMBER 5 | NOVEMBER 2019 1031
CI 2.94–10.40; P = 1.4 × 10−7), but could not better explain the 
CBZ- SCAR association than HLA-A*31:01. The AA is shared by 
the A*33 and A*31 alleles.16 Conditional analysis to isoleucine73 or 
to HLA-A*31:01 revealed that isoleucine80 in the B locus is a new 
independent factor, and it is shared with HLA-B*57:01 among 
other HLA B alleles.16 After conditioning on both the sites, the 
residual independent association signal was still accounted for by 
rs116071718 in the MUC22 gene (Table S4). These AA associa-
tions have not previously been found to be implicated in genetic 
predisposition to other adverse drug reactions.
GWAS of CBZ- SCAR clinical subtypes
We stratified the CBZ- SCAR cases by clinical phenotypes (AGEP, 
DRESS, and SJS/TEN; see Methods). The AGEP analysis was 
not performed because we had only two cases, although it is worth 
noting that one of the two cases was positive for HLA-A*31:01.
In the CBZ- DRESS subgroup, HLA-A*31:01 and its 
proxy SNP, rs192543598, reached genomewide significance 
(PHLA-A*31:01  =  2.1  ×  10
−9 and Prs192543598  =  2.4  ×  10
−13). 
Consistent with the literature,17 HLA-A*31:01 showed a stron-
ger effect with CBZ- DRESS than with SJS/TEN (OR  =  12 vs. 
OR  =  2.5, respectively; Table 4) with no significant association 
in the latter group. There was no other phenotype- specific ge-
nomewide significant association for both DRESS and SJS- TEN 
(Figure S5).
The effect of rs187926838 in the ALK gene was conserved 
among the CBZ- SCAR clinical subtypes (Table S5). We also 
found that the SJS/TEN phenotype showed an MHC- region- wide Ta
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Figure 1 Scatterplot representing the first two principal components 
(PCs) of the current study cohort. Colored dots are the cases divided 
by clinical phenotypes and the gray dots are the controls. The 
controls cluster in four groups representing the Italian, Spanish, 
United Kingdom, and Swedish major control populations. AGEP, acute 
generalized exanthematous pustulosis; DILI, drug- induced liver injury; 
DRESS, drug reaction with eosinophilia and systemic symptoms; 
SJS/TEN, Stevens- Johnson syndrome/toxic epidermal necrolysis.
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significant association with HLA-B*57:01 (OR  =  6.2; 95% CI 
2.47–15.37; P  =  9.9  ×  10−5). HLA-B*57:01 was in strong LD 
(r2 = 0.8) with the most highly associated SNP in the MHC region 
(rs116347890; OR = 11.0; 95% CI 4.62–26.42; P = 6.6 × 10−8) 
but was independent of HLA-A*31:01 (OR = 6.4; 95% CI 2.55–
16.11; P = 7.6 × 10−5) after conditioning on HLA-A*31:01. The 
polymorphic AA position 97 showed an association when valine 
was present (OR = 6.0; 95% CI 2.45–15.18; P = 0.0001). Valine97 
is specific for HLA-B*57:01, HLA-B*57:02, and HLA-B*57:03 
and other very rare B57 alleles.16
GWAS of CBZ- DILI
GWAS analysis of 12 European CBZ- DILI cases against 8,438 
European controls did not identify a genomewide association 
because of limited power. However, 33% of cases were HLA-
A*31:01 carriers (OR = 7.3; 95% CI 2.47–23.67; P = 0.0004), al-
though the OR was less than that seen with DRESS (OR = 12.9). 
Our prediction of the association with HLA-A*31:01 was fully 
confirmed by HLA sequencing in 11 cases (DNA was no lon-
ger available in one patient). CBZ- DILI cases did not show an 
association with rs187926838 (in the ALK gene), distinct from 
that seen with CBZ- SCAR cases (Table S5). The most signif-
icant AA residues associated with CBZ- DILI were isoleucine73 
(OR = 7.29; 95% CI 2.578–20.6; P = 0.0002) and threonine9 
(OR  =  5.5; 95% CI 2.31–13.14; P  =  0.0001) at the HLA-A 
locus. The two residues were in LD (P73I conditional to 9T = 0.2). 
Moreover, there was enrichment of HLA-A*31:01 carriers in the 
10 patients with CBZ- SCAR with liver involvement compared 
with the remaining cases (25% vs. 12%, respectively).
Taking all the cases of CBZ- induced hypersensitivity reactions 
(SCAR and DILI) together, the risk of developing either DILI 
or SCAR when given CBZ was eightfold higher in cases carrying 
HLA-A*31:01 (OR = 8.2; 95% CI 4.56–14.66; P = 1.8 × 10−12; 
Table 4).
DISCUSSION
In the current study, we show that HLA-A*31:01 is the strongest 
predictor of CBZ- SCAR in a European- ancestry population, ex-
tending our previous study in Northern Europeans10 to include 
Southern Europeans. In addition, we also show that (i) HLA-
A*31:01 seems to predispose to CBZ- induced liver injury, and (ii) 
a variant in the ALK gene was associated with an increased risk of 
CBZ- SCAR but not CBZ- DILI.
Our finding of the association between CBZ- SCAR and HLA-
A*31:01, initially reported in 2011,10 has also been reported by 
Amstutz et al.18 in a multiethnic North American pediatric cohort 
Figure 2 Manhattan plot displaying the results of the meta- analysis of British and broadly European carbamazepine– serious cutaneous 
adverse reactions genomewide association study analyses. Single nucleotide polymorphisms in red have a significance level < 5 × 10−8.
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Table 3 Imputed HLA alleles attaining nominal evidence of association (P < 0.01) with CBZ hypersensitivity in combined 
meta- analysis of 43 patients and 10,701 controls of European ancestry
HLA allele
Phase I Phase II Combined meta- analysis
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Cochran’s Q 
P value
Frequency 
in controls
HLA-A*31:01 16.9 
(5.40–52.40)
1.0 × 10−6 5.3 
(2.29–12.40)
9.9 × 10−5 8.0 
(4.10–15.80)
2.2 × 10−9 0.11 0.02
HLA-B*51:01 2.8 (0.80–9.60) 0.10 3.7 
(1.87–7.28)
0.0002 3.5 
(1.91–6.27)
5.6 × 10−5 0.70 0.06
HLA-C*15:02 2.1 (0.23–16.5) 0.47 4.1 
(1.74–9.92)
0.001 3.7 
(1.68–8.35)
0.002 0.56 0.02
HLA-
DPB1*09:01
4.9 
(0.70–35.60)
0.12 4.5 
(1.17–17.60)
0.03 4.6 
(1.51–14.20)
0.007 0.96 0.009
CBZ, carbamazepine; OR, odds ratio.
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and by Genin et al.17 in a European SCAR cohort. In our study, 
HLA-A*31:01 was a stronger risk factor for DRESS than SJS/TEN, 
in line with Genin et al.17 (OR = 57.6 vs. OR = 4.4, respectively) 
and Amstutz et al.18 (OR = 31.5 vs. OR = 2.8, respectively), but 
not with our original study (OR = 12 vs. OR = 25, respectively)10 
where numbers were much smaller. It is likely that HLA-A*31:01 
is the most important shared risk factor across CBZ hypersen-
sitivity phenotypes, with the strongest predisposition being to 
DRESS. Indeed, our meta- analysis shows that HLA-A*31:01 car-
riers have eightfold higher risk of developing CBZ- SCAR than 
noncarriers. Interestingly, a recent prospective study in Japan was 
able to show that pre- prescription genotyping for HLA-A*31:01 
reduces the incidence of CBZ hypersensitivity reactions.19 Taken 
together, the overwhelming evidence of the role of HLA-A*31:01 
in predisposing to CBZ- SCAR shows that there is a need to imple-
ment its use in clinical settings, as outlined in the recent Clinical 
Pharmacogenetics Implementation Consortium guideline.20 
Independent of the HLA-A*31:01 association, we identified a re-
sidual effect in the MHC region mapping to MUC22 gene (lead 
SNP rs116071718). MUC22 codes for panbronchiolitis- related 
mucin- like protein 1 and has been associated with SJS/TEN 
caused by a variety of drugs, including CBZ in European patients.21 
Its role in SCAR needs further investigation. We also found that 
HLA-B*51:01 was the second most significant HLA allele. HLA-
B*51:01 has already been reported to be marginally associated 
with CBZ- SCAR12–14 and more recently with SCAR due to other 
drugs.22 HLA-B*51:01 together with HLA-A*31:01 and HLA-
C*15:02 constitute a haplotype that has a larger OR than each sin-
gle allele (Table S3). This is an interesting finding, which suggests 
that in vivo, the T-cell response to CBZ- derived antigens requires 
cooperativity between different HLA alleles, as we have previously 
demonstrated in an HLA-A*31:01-positive patient.23
We also identified an association between CBZ- induced SJS/
TEN and HLA-B*57:01. This allele is a well- known risk factor 
for other CD8+  T- cell- mediated reactions, including abacavir 
hypersensitivity syndrome24,25 and flucloxacillin- induced DILI,26 
and more recently, DILI induced by two other drug combinations, 
pazopanib and a combination of antituberculosis and anti- HIV 
drugs.27,28 Given that the association with CBZ- induced SJS/
TEN was not genomewide significant, it needs replication in other 
cohorts. Interestingly, our finding of the association of valine97 
with CBZ- SJS/TEN is in line with the association of valine97 with 
flucloxacillin- DILI,29 suggesting that the binding site of HLA-
B*57:01 may be promiscuous for a number of drugs, which would 
be in keeping with the increasing number of reports of immune- 
mediated reactions associated with this allele.
We have, we believe, for the first time evaluated whether HLA-
A*31:01 is a risk factor for DILI. Taking all cases of DILI into ac-
count, the carriage rate of HLA-A*31:01 was 33% with an OR of 
7, higher than that found in association of HLA class II alleles with 
lumiracoxib- induced DILI.30 Interestingly, CBZ- SCAR and CBZ- 
DILI also shared the most significant AA, isoleucine.73 Isoleucine73 
is a cryptic epitope specific for A31 and A33 antigens.31 Position 73 
is not normally exposed. When the antigen changes its conforma-
tion and β2m and peptide dissociate from the heavy chain, isoleu-
cine73 is externalized with the potential to lead to an autoimmune 
reaction.32 Interestingly, HLA-A*33:01 and HLA-A*33:03 have re-
cently been associated with DILI due to several unrelated drugs.33 
The association with HLA-A*31:01, however, was not genomew-
ide significant, which may reflect the small numbers studied. It may 
also reflect that the mechanism of antigen presentation (be it the 
parent drug or metabolite) differs between the skin and liver given 
the major role of the liver in drug metabolism and its ability to form 
chemically reactive intermediates.34 Further work in larger num-
bers of patients with CBZ- DILI, together with mechanistic stud-
ies, will be needed to understand the role of drug/metabolites as 
antigens in the context of different drug metabolizing and antigen 
presentation capabilities, and, indeed, whether these differences are 
responsible for the remarkable organ- specificity of the reactions 
and their severity seen in different patients.
A tantalizing association that we have identified in our meta- 
analysis (that did not pass genomewide significance after permu-
tation) that was observed in the SCAR but not in the DILI cases 
was with uncommon variants in the ALK gene, which codes for the 
anaplastic lymphoma kinase gene. Somatic mutations in the ALK 
gene have been identified in different cancers,35 including lung 
cancer, which has led to the development of ALK- inhibitors for 
therapy. The product of the ALK gene, a receptor tyrosine kinase 
belonging to the insulin receptor family, seems to be important for 
the balance between proliferation and apoptosis.36 Furthermore, 
the associated region falls within a keratinocyte- specific predicted 
insulator (Figure S6). Given that ALK is important in cellular pro-
liferation and cell death and shows ubiquitous tissue distribution 
(http://www.prote inatl as.org/ENSG0 00001 71094-ALK/tissue), 
it may have an important role in T- cell proliferation and keratino-
cyte death, both important in the pathogenesis of SCAR.
In conclusion, we have provided further data regarding ge-
netic factors predisposing to different CBZ adverse reaction 
Table 4 Association effect size of HLA-A*31:01 across different clinical phenotypes
Clinical groups N OR (95% CI) P value
Allele frequency in 
cases
Allele frequency in 
controls
SJS/TEN 16 2.4 (0.55–10.59) 0.2 0.06 0.02
DRESS 25 12.9 (5.58–29.78) 2.1 × 10−9 0.14 0.02
DILI 12 7.3 (2.47–23.67) 0.0004 0.17 0.02
All clinical phenotypes 
(SCAR and DILI)
55 8.2 (4.56–14.66) 1.8 × 10−12 0.14 0.02
DILI, drug- induced liver injury; DRESS, drug reaction with eosinophilia and systemic symptoms; OR, odds ratio; SCAR, serious cutaneous adverse reaction; SJS, 
Stevens- Johnson syndrome; TEN, toxic epidermal necrolysis.
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phenotypes, which are thought to have an immune pathogenesis, 
namely SCAR and DILI. We have extended our studies to include 
Southern Europeans in addition to our previous study in Northern 
Europeans10 and included an analysis of CBZ- DILI. We have also 
identified novel associations with the ALK and MUC22 genes, 
which require further validation and experimental investigation to 
determine the mechanisms. It is possible that there are also other 
genetic factors outside the MHC region, but we may not have had 
the statistical power to detect them in this study. It is, therefore, im-
portant that further work also involves a trans- ethnic meta- analysis 
of the GWAS in diverse populations, which have been undertaken 
to date, to fully assess differences in the genetic architecture of 
CBZ adverse reactions between ancestries and, more precisely, lo-
calize the underlying causal alleles.
METHODS
Study design overview
Our study combines results from two GWAS conducted in subjects 
with ancestry from Northern Europe, Italy, and Spain. All participants 
provided written informed consent and each study was approved by the 
appropriate national or institutional ethical review boards. Because the 
reactions have a very low prevalence, we used general population samples 
as study controls.
British CBZ- SCAR GWAS
The study included 14 patients with CBZ- hypersensitivity of Northern 
European descent of the 21 recruited at the University of Liverpool, as 
described by McCormack et al.10 A total of 2,263 population controls 
of Northern European descent from the Wellcome Trust Case Control 
Consortium were utilized. The other Liverpool samples (n  =  7) origi-
nally described were excluded either because of population stratification 
issues or because two patients had DILI rather than skin involvement 
(and so have been included in the liver analysis).
Broadly European CBZ- SCAR GWAS
The study included a total of 29 CBZ- SCAR samples obtained from 
two available sources: 3 cases were from the PGX40001 study37 and 26 
were newly recruited between 2009 and 2013 as part of the International 
Consortium of Drug Hypersensitivity (ITCH) study. The ITCH study 
was run under the auspices of the International Serious Adverse Event 
Consortium, involving 12 recruitment centers in Europe, Australia, and 
South America. Clinical inclusion criteria for all ITCH- related SCAR 
cases were as described by our previous phenotype standardization pro-
tocol for drug- induced skin injury.38 All patient phenotypes were inde-
pendently adjudicated by the co-authors N.S. and P.F. Further clinical 
details are provided in Table 1.
For this group, a total of 8,438 population controls of European de-
scent were selected from the Wellcome Trust Case Control Consortium 
(not overlapping with samples from the British cohort), the population 
reference sample (POPRES),39 the PGX40001 study,37 the Spanish 
Bladder Cohort (dbGaP phs000346.v1),40 the Hypergenes cohort 
(http://www.hyper genes.eu), the National Spanish DNA Bank co-
hort (http://www.banco adn.org/), the Swedish Twin Registry cohort 
(http://ki.se/en/resea rch/the-swedi sh-twin-registry), LAM30004 
study,37 TSI (Hapmap data), and the iSAEC Italian Penicillin Tolerant 
Cohort (IPTC).
Broadly European CBZ- DILI GWAS
As part of the phase II study, we also collected 12 patients of European 
descent with CBZ- DILI, in which the liver was involved by itself. The 
cases were recruited from two large international DILI consortia: 
iDILIC and DILIN,33 whereas two other cases were as described 
previously.10 The iDILIC cases were evaluated by application of 
the Council for International Organizations of Medical Science 
(CIOMS) scale, also called the Roussel Uclaf Causality Assessment 
Method (RUCAM), and by expert review by a panel of three hepa-
tologists. Only cases having at least possible causality (score ≥ 3) were 
included in the study.33 DILIN causality assessment is determined by 
a panel of three hepatologists who independently assign a causality 
score ranging from 1 (definite) to 5 (unlikely) as well as a severity score 
ranging from 1 (mild) to 5 (fatal), as previously described.33 Besides 
the DILI phenotype, DILIN and iDILIC also collected additional 
clinical information, including the occurrence of eosinophilia and cu-
taneous involvement. The cases were compared with the 8,438 phase 
II population controls of European descent.
Genotyping of cases and controls
Out of the cumulative 43 CBZ- SCAR cases, three PGX40001 cases 
were previously genotyped with Illumina 1M Duo chip.41 DNA 
from the rest of British and broadly European cases was extracted 
from whole blood and stored in the Wolfson Centre for Personalized 
Medicine in Liverpool. Genomewide genotyping was profiled by the 
Illumina Infinium HumanCoreExome Bead Chip for 16 cases and by 
Illumina HumanOmniExpress Bead Chip for 24 cases at the Broad 
Institute, Boston. Among the CBZ- DILI cases, three cases were previ-
ously genotyped with Illumina 1M Duo Chip, whereas two cases were 
newly profiled by HumanCoreExome Bead Chip and seven cases by 
HumanOmniExpress Bead Chip at the Broad Institute, Boston.33 A 
total of 10,701 previously genotyped population controls were cumu-
latively used in British and broadly European cohorts. Information 
about the genotyping platform used by each of the control cohorts is 
reported in Table S6. For each of the sample batches (defined as a set 
of subjects—either cases or controls—genotyped together by the same 
array), quality control was conducted at both SNP and subject levels 
before performing the imputation as previously described.41 Analysis 
of population structure was performed by the EIGENSTRAT pack-
age version 3.0.42 Pre- phasing and imputation were performed in 
batches by dividing the cases and controls according to genotyping 
platform, using SHAPEIT (version v2.r727)43 and IMPUTE2 (ver-
sion 3)44 with 1000 Genomes Project (release version 3) as reference.43 
For downstream analysis, we used best- guess genotypes retaining im-
puted genotypes with posterior probability >  0.9. Detailed methods 
are outlined in the Supplementary Materials.
Association analysis and meta- analysis
We tested for association of each SNP with CBZ- SCAR, separately in 
British and broadly European GWAS, in a logistic regression frame-
work, under an additive genetic model, with adjustment for the principal 
components from smartPCA to account for population structure using 
PLINK version 1.07.45 No other additional covariates were included in 
the model because we did not have clinical information for controls. 
Association summary statistics from the two phases were combined 
using effective sample size weighted z- score fixed- effects meta- analysis, 
implemented in METAL.46 Allelic ORs across the two phases were ob-
tained through inverse- variance weighting of effect sizes, with hetero-
geneity assessed with Cochran’s Q statistic,47 implemented in METAL. 
We reported only those SNPs that attained, in addition to genomewide 
significance, nominal evidence of association (P < 0.05) with the same 
direction of effect on CBZ- SCAR in both GWAS phases (internal 
validation). Furthermore, we tested for association of each SNP with 
CBZ- SCAR clinical subtypes: SJS/TEN in phase II GWAS and DRESS 
across both phases in the same meta- analysis framework. We also tested 
for association of each SNP with CBZ- DILI in phase II GWAS, in a 
logistic regression framework, under an additive genetic model, with 
adjustment for the principal components to account for population 
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structure. Genomewide significance was defined using a common 
threshold of P < 5 × 10−8. To account for the small sample size and the 
disproportionate case/control ratio, we applied a permutation approach 
for genomewide significant signals. In particular, we randomly permuted 
genotypes among individuals within the same phase of the design, tested 
for association, and then meta- analyzed. We applied 5 × 108 permuta-
tions to demonstrate genomewide significance. All detailed analyses and 
Manhattan plots were performed with R version 3.0.2.14
HLA imputation, genotyping, and analysis
For each batch, HLA alleles were inferred using HLA genotype imputa-
tion with attribute bagging48 using the reference predictor panels specific 
for the genotyping chip. AA changes were inferred by SNP2HLA using 
reference data collected by the Type 1 Diabetes Genetics Consortium.49 
We tested for association of carriage of each allele/AA/specific HLA 
haplotypes with CBZ- SCAR, CBZ- SCAR subtypes, and CBZ- DILI 
using the same methods described above. MHC significance was defined 
using the Bonferroni correction threshold of P < 0.00025 accounting for 
200 observed HLA alleles across loci (0.05/200). Conditional analyses 
in the MHC region were undertaken and the genotypes at the condition-
ing SNP(s) were included as covariates under an additive model. Fixed- 
effects meta- analyses across the two phases of GWAS were performed 
using the methods described above for unconditional analyses. High-
resolution genotyping of HLA loci was performed on all DILI cases by 
Histogenetics (Ossining, NY), as previously described.33
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Supplementary Methods, Figures, and Tables.
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